Target/Pathway Enrichment Report

Mapping Details for your submissionhelp

# Active Inactive
Your Submission 2267 356960
Mapped to Target 2271 356960
Mapped to Reactome 2271 356960
Mapped to GO 2271 356960

Table 1. Target/MultiTarget Enrichment help

View Full Report

# TARGET/MULTI-TARGET Odds Ratio p-value kA size
Active
kB size
InActive
1 gene: ALPPL2 inhibitor (gi:157266296, 6 assays integrated)
22.15 1.54e-19 22 2271 129 294963
2 gene: ATAD5 inhibitor (gi:116283940, assay: 624249)
20.63 2.34e-38 44 2271 277 294963
3 gene: ATAD5 inhibitor (gi:116283940, assay: 624248)
19.95 4.06e-49 57 2271 371 294963
4 gi:121945198 inhibitor (assay: 540248)
17.81 5.71e-105 127 2271 926 294963
5 interaction (assay:429 ) inhibitor
gi:4261762
gene: HSP90AA1 gi:154146191

17.43 8.81e-16 20 2271 149 294963

Table 2. Pathway Enrichment help

View Full Report

# GO Term Odds Ratio p-value kA size
Active
kB size
InActive
1 (inhibitor) Pyruvate metabolism 6.47 1.06e-33 77 1969 1176 194579
2 (inhibitor) Pyruvate metabolism and Citric Acid (TCA) cycle 6.47 1.06e-33 77 1969 1176 194579
3 (inhibitor) Meiotic recombination 5.95 2.78e-191 433 1969 7181 194579
4 (ALL) Chemokine receptors bind chemokines 5.18 3.55e-23 65 1969 1239 194579
5 (inhibitor) Effects of PIP2 hydrolysis 4.91 0.011 10 1969 201 194579

Table 3. GO term Enrichment help

View Full Report

# GO Term Odds Ratio p-value kA size
Active
kB size
InActive
1 (inhibitor) meiotic cell cycle 13.4 4.84e-131 182 2035 1459 218762
2 (inhibitor) nucleotide-excision repair 13.13 3.80e-128 180 2035 1473 218762
3 (inhibitor) ureteric bud development 11.47 1.55e-134 203 2035 1902 218762
4 (inhibitor) inner ear development 11.16 1.88e-132 203 2035 1954 218762
5 (inhibitor) transcriptional repressor complex 9.23 7.28e-112 193 2035 2246 218762